Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of 18 ) is an important and effective approach to treating melanomas. A new specific small molecule inhibitor of BRAF V600E , PLX3603, showed potent melanoma growthinhibiting characteristics in preclinical studies and is currently under clinical investigation. In this study we investigated the feasibility of 18 F-FDG and 18 F-FLT-PET to monitor the early effects of the BRAF V600E inhibitor in mice with melanoma xenografts. SCID/beige mice with subcutaneous (s.c.) A375 melanoma xenografts, expressing BRAF V600E , received the BRAF V600E inhibitor twice daily orally (0, 25, 50 and 75 mg/kg). At 1, 3 and 7 days after start of therapy, the uptake of 18 F-FDG and 18 F-FLT in the tumor and normal tissues was determined in ex vivo tissue samples. Serial 18 F-FDG and 18 F-FLT-PET scans were acquired of animals at 1 day before and 1, 3 and 7 days after start of treatment with 75 mg/kg BRAF V600E inhibitor. A dose-dependent decrease in 18 F-FDG uptake in the A375 tumors was observed by ex vivo biodistribution analysis. Administration of 75 mg/kg BRAF inhibitor for 1, 3 and 7 days resulted in a significantly decreased
INTRODUCTION
Metastatic melanoma is an aggressive disease and patients have a poor prognosis. The median survival time for patients with metastasized melanoma is a mere 8-9 months and 3-year survival is <15% (1) . Only a few effective therapies for metastatic melanoma are available, such as chemotherapy with decarbazine and immunotherapy with interferon-α and interleukin-2, although their advantages in terms of survival and response rate are moderate.
In the search for new therapy targets, a genomic screen for mutations in signaling molecules in melanoma revealed numerous mutations, particularly in members of the mitogen-activated protein kinase (MAPK) pathway (2) . Mutations in the NRAS gene have been observed in~20% of all melanomas, whereas mutations in the BRAF gene have been observed in~50% of all melanomas. These mutations lead to constitutive kinase activation, independent of upstream signaling. This continuous activation of the NRAS/BRAF/MAPK/ERK signal transduction pathway stimulates melanocyte proliferation and is therefore a key driving force for the development of melanoma. Nearly 90% of all of the mutations observed in the BRAF gene are a single-point mutation, which results in a valine-to-glutamic acid substitution at residue 600 (BRAF V600E ). Owing to its high prevalence, the selective inhibition of the oncogenic BRAF V600E is a prime therapeutic approach for treatment of metastatic melanoma (3).
Vemurafenib (PLX4032) is the first selective small molecule inhibitor of BRAF V600E that has been approved for clinical use to treat patients with BRAF V600E -positive metastatic melanoma. In clinical trials, treatment with vemurafenib resulted in a response rate of 53-81%, a median overall survival (OS) of 13.2-15.9 months, a median progression-free survival (PFS) of 6.9 months and a 63% decrease in risk of death compared with treatment with decarbazine (median OS of 9.6 months and a median PFS of 1.6 months) (4-7). Dabrafenib, another specific BRAF V600E inhibitor, showed similar clinical response rates (50%) and median PFS (5.1 months) to vemurafenib (8) . Although not life-threatening, treatment with vemurafenib and dabrafenib may result in serious adverse events, including the increased incidence of cutaneous squamous cell carcinoma (cuSCC, in approximately 20% of the patients) and keratoacanthoma and the possible subsequent development of additional malignant lesions (9) .
Recently, a new inhibitor of BRAF V600E (PLX3603) was developed, which in pre-clinical studies showed promising melanoma growth-inhibiting characteristics. PLX3603 inhibited cell proliferation and MAPK signaling in several BRAF V600E -expressing cancer cell lines more potently than vemurafenib and in mice with melanoma xenografts it showed increased anti-tumor activity in vivo compared with vemurafenib (10). More importantly, PLX3603 had no effect on the tumor growth of A431 SCC xenografts, whereas vemurafenib treatment stimulated its growth (10) . A phase I clinical dose escalation study showed an improved safety profile for PLX3603 (11) . No dose-limiting toxicities were observed, adverse events were mild to moderate and only 7% of the patients developed cuSCC (11) . Efficacy of PLX3603 treatment was encouraging: 18 out of 44 patients showed stable disease, while 14 patients showed a partial response (11) .
Continued activation of the MAPK-pathway, owing to mutated BRAF, has been directly linked to activation of glucose metabolism and proliferation. For instance, ERK stimulates glucose metabolism via the LKB1-AMP pathway and the expression of the glucose transporter, GLUT1 (12) (13) (14) . Mutant BRAF positive cell lines show a decreased expression of cyclin D1 and a complete and rapid inhibition of the G 1 -S transition (15 (10) . PLX3603 was resuspended in 1% hydroxypropylcellulose, pH 4 (Klucel-LF, Hercules Incorporated, Wilmington, DE, USA) and orally administered within 30 min after constitution of the suspension.
Cell Culture
The V600E mutant BRAF-expressing human melanoma cell line A375 (CRL-1619, American Type Culture Collection, Manassas, VA, USA) was cultured in Dulbecco's modified Eagle medium, high glucose (Gibco, Carlsbad, CA, USA) supplemented with fetal calf serum (10%). Cells were incubated at 37°C in 5% CO 2 and 95% relative humidity.
Animals
All animal experiments described in this study were approved by the institutional review board and conducted according to their guidelines. Female SCID/beige mice were obtained from Taconic Farms (Germantown, NY, USA) and weighed 20-25 g (6-8 weeks old) upon arrival. Mice were allowed to acclimatize for 1 week to the new housing conditions. Mice were housed with five animals per individual ventilated cage under standard housing conditions (temperature 20-24°C, 12 h light-dark cycle and ad libitum access to animal chow and water).
2.4.

F-FDG and F-FLT Biodistribution Analysis
Animals were s.c. injected with 10 × 10 6 A375 cells in the right flank. After 1 week tumor xenografts were palpable. Tumor size was measured twice weekly by digital calipers and calculated as 4/3 · π · (length/2) · (width/2) · (height/2). Fourteen days after cell inoculation tumor size reached an approximate volume of 30 mm 3 and PLX3603 treatment was started. Tumor size was measured at 1, 3 and 7 days after the start of PLX3603 administration. PLX3603 was administered orally twice daily at a 12 h interval at doses of 25, 50 and 75 mg/kg. The control group received vehicle only (1% hydroxypropylcellulose, pH 4; n = 5). At 1, 3 and 7 days after the start of PLX3603 treatment (a total of 3, 7 and 15 PLX3603 administrations, respectively), and 4 h after the last PLX3603 administration, the animals received 10 MBq 18 F-FDG or 18 
F-FLT-PET/CT
Two groups of mice with s.c. A375 tumors were treated with PLX3603 at 75 mg/kg as described above and PET/CT images were acquired at various time points; 1 day prior to the start of PLX3603 administration, 18 F-FDG (n = 3) and 18 F-FLT-PET/CT (n = 3) scans were made. The 18 F-FDG and 18 F-FLT-PET/CT scans was repeated in the same animals at 1, 3 and 7 days after the start of PLX3603 administration, 4 h after the last PLX3603 administration. In short, animals received 10 MBq 18 F-FDG or 18 F-FLT i.v. via the tail vein and animals that received 18 F-FDG were immediately anesthetized with 2% isoflurane-O 2 and kept at 37°C. PET/CT scans were acquired 1 h after 18 F-FDG and 18 F-FLT injection with an Inveon animal PET/CT scanner (Siemens Preclinical Solutions, Erlangen, Germany), having an intrinsic special resolution of 1.5 mm (16) . The animals were placed in a supine position on a heated mattress and kept under isoflurane anesthesia throughout the PET/CT scan procedure. PET scans were acquired for 15 min, followed by CT scans for anatomical reference (spatial resolution, 113 μm; 80 kV; 500 μA; exposure time, 300 ms). Scans were reconstructed using Inveon Acquisition Workplace software (version 1.5; Siemens Preclinical Solutions) using a three-dimensional ordered subset expectation maximization/maximum a posteriori algorithm with the following parameters: matrix, 256 × 256 × 159; pixel size, 0.43 × 0.43 × 0.8 mm; and β-value 1.5, with uniform variance. After scan reconstruction, regions of interest (ROI) around the A375 tumors were manually drawn and the activity in the volume of interest (VOI) with a threshold set at 50% of the maximum activity in the ROI was determined (VOI 50% ). The %ID/g of the VOI 50% was determined by calculating the average of the percentage injected dose per gram for the voxels within the VOI 50% , assuming a density of 1 g/ml.
Immunohistochemistry
Directly following dissection, the A375 tumors were fixed in 4% paraformaldehyde. Tumors were dehydrated in a graded series of ethanol, embedded in paraplast and 6 μm sections were cut. Sections were stained for phosphorylated ERK (pERK), glucose transporter 1 (GLUT1) and Ki67, a marker for cell proliferation. In short, antigen was retrieved in citrate buffer (10 mM, pH 6, 95-100°C), after which sections were incubated with H 2 O 2 (3%) to inactivate endogenous peroxidase activity. Sections were pre-incubated with normal goat serum (20%, pERK and GLUT1) or normal swine serum (20%, Ki67) to block nonspecific binding sites.
Sections were incubated with rabbit-anti-GLUT1 antibody (1:200, R13-9052-P, Neomarkers, Fremont, CA, USA), rabbit-antipERK antibody (1:100, 4376, Cell Signaling Technology, Danvers, MA, USA) or rabbit-anti-Ki67 antibody (1:100, RM9106, Thermo Scientific, Waltham, MA, USA ) for 2 h. Sections incubated with the GLUT1 and pERK antibodies were incubated with biotinylated goat-anti-rabbit secondary antibody (1:200, VectaStain, Vector Laboratories, Burlingame, CA, USA) for 1 h and followed by incubation for 30 min with VectaStain ABC reagent. The sections incubated with the Ki67 antibody were incubated with swineanti-rabbit-peroxidase antibody (1:500, Dako, Glostrup, Denmark). Peroxidase activity was stained with 3,3′-diaminobenzidine (Powervision DAB, Immunologic, Duiven, The Netherlands) in the presence of H 2 O 2 and all sections were counterstained with hematoxylin.
Statistical Analysis
All data are presented as mean values ± standard deviation. The size of the experimental groups (n) is given in parentheses. Differences between groups were assessed by one-way ANOVA and Bonferroni post hoc test or by Student's t-test. Statistical significance was set at p < 0.05 (two-tailed) and probabilities are indicated by asterisks (* p < 0.05; ** p < 0.01; *** p < 0.001).
RESULTS
Effect PLX3603 on Tumor Growth
Administration of PLX3603 inhibited A375 tumor growth. Compared with vehicle-treated animals, a dose of 25 mg/kg resulted in a 34% decrease in tumor size after 7 days of treatment (p = 0.004; Fig. 1 ). Higher doses (50 and 75 mg/kg) resulted in 39 and 29% tumor size reduction after 3 days of treatment (p = 0.003 and p = 0.02, respectively) and 56 and 49% after 7 days of treatment (p < 0.0001; Fig. 1 ).
18 F-FDG and 18 F-FLT Biodistribution Studies
The biodistribution data of 18 F-FDG and The administration of PLX3603 had no consistent effect on 18 F-FLT uptake in the tumor (Fig. 3): 18 F-FLT uptake in the A375 tumor decreased after treatment with 75 mg/kg PLX3603 for 1 and 7 days (36%, p = 0.041 and 61%, p = 0.039, respectively). However, this decrease was accompanied by decreased blood levels of 18 F-FLT (35%, p = 0.031 and 32%, p = 0.014, respectively; Fig. 3 ). It appears that the reduction of uptake of 18 F-FLT in the tumor was the result of enhanced clearance of 18 F-FLT from the blood (Fig. 3) . Indeed, 18 F-FLT tumor-to-blood ratios did not significantly change compared with tumor-to-blood ratios of vehicle treated animals after 1 (p = 0.933), 3 (p = 0.798) or 7 days (p = 0.133) of treatment with PLX3603 (data not shown).
18 F-FDG and 18 F-FLT-PET/CT
18 F-FDG uptake in A375 melanoma xenografts was clearly visualized in the 3D PET/CT images (Fig. 4a) . Three days after the start of PLX3603 treatment, 18 F-FDG uptake in the tumor was lower. This decrease in 18 F-FDG uptake was sustained up to 7 days of treatment.
18 F-FDG uptake was further observed in muscle, brown adipose tissue, kidney, intestines, heart and brain, 18 F-FDG uptake in tail is likely to be injection related. Quantification of the 18 F-FDG-PET signal in the A375 melanoma xenograft VOI showed a significantly decreased 18 F-FDG uptake after 3 (40%, P = 0.012) and 7 days (38%, P = 0.006) after the start of treatment, compared with basal 18 F-FDG uptake (Fig. 4b) . 18 F-FLT PET/CT images revealed a relative low uptake of 18 F-FLT in A375 melanoma xenografts, which was not further reduced after treatment with PLX3603 (Fig. 5a ). High uptake of 18 wileyonlinelibrary.com/journal/cmmi tumor VOI confirmed that the 18 F-FLT uptake in the tumor did not change during the treatment with PLX3603 (Fig. 5b) .
Immunohistochemistry
Staining for pERK in A375 melanoma xenografts was reduced after 3 days of treatment with 75 mg/kg PLX3603, indicating inhibition of the MAPK pathway (Fig. 6) . The decreased uptake of 18 F-FDG in A375 tumors was not accompanied by reduced expression of GLUT1 (data not shown), which may be explained by the relatively small changes in 18 F-FDG uptake and the involvement of other proteins, such as hexokinases, in cellular uptake of 18 F-FDG. Similarly, no change in Ki67 expression was observed in tumors of animals treated with PLX3603, which may be due 
DISCUSSION
The dose-and time-dependent effects of PLX3603 treatment on 18 F-FDG-uptake in A375 xenografts observed in this study, show that 18 F-FDG-PET is a potential imaging biomarker to noninvasively evaluate the pharmacodynamic effects of the BRAF V600E inhibitor PLX3603 on melanoma in an early phase, whereas these effects could not be assessed with 18 F-FLT-PET. Ex vivo biodistribution analysis revealed a significant 40% decrease in 18 F-FDG uptake as early as 1 day after administration of PLX3603 at 75 mg/kg, before any change in tumor size was apparent. This decrease persisted during the 7 day dosing regimen wileyonlinelibrary.com/journal/cmmi (35 and 51% at 3 and 7 days, respectively). Lower doses of PLX3603 also resulted in a reduced 18 F-FDG uptake in the tumor after longer exposure: a dose of 50 mg/kg resulted in a decreased 18 F-FDG uptake after 3 days, whereas at a dose of 25 mg/kg 18 F-FDG uptake only decreased significantly after 7 days. Immunohistochemical analysis of the tumor showed a decreased expression of pERK after 3 days of treatment with PLX3603, confirming a pharmacological effect of PLX3603 on the inhibition of the MAPK pathway.
The observed effects of PLX3603 on 18 F-FDG uptake in A375 melanoma xenografts could also be monitored by in vivo 18 F-FDG-PET imaging. After 3 and 7 days of treatment with 75 mg/kg PLX3603, a 40 and 38% reduction in 18 F-FDG uptake in the A375 xenografts was detected with 18 F-FDG-PET, which is comparable to the ex vivo biodistribution analysis. Other small-molecule BRAF V600E inhibitors, RAF256 (100 mg/kg) and vemurafenib (50 mg/kg), also induced reduced 18 F-FDG uptake in A375 melanoma xenografts (17, 18) . In patients with metastatic melanoma, treatment with vemurafenib for 15 days resulted in an 87% reduction of 18 F-FDG uptake, although the reduced uptake did not predict responses as measured by RECIST (19) . The results of the present study show that 18 F-FDG-PET can be used as pharmacodynamic marker to monitor the dose response and time course of the response of PLX3603, and therefore 18 F-FDG-PET can be a useful tool in the clinical development of PLX3603, although caution is needed when extrapolating data from nude mouse xenograft tumor models to melanoma in men.
A few studies have shed a light on the mechanism how BRAF V600E inhibition could lead to the reduction of uptake of 18 F-FDG in the tumor. Inhibition of the MAPK-pathway, including inhibition via BRAF, is directly linked to pathways that regulate glucose metabolism. For instance, inhibition of BRAF V600E results in the activation of the LKB1-AMP pathway, via ERK, which negatively influences glucose metabolism (13) .
Although in vitro studies have shown reductions in 18 F-FLT uptake in some melanoma cells lines after treatment with the BRAF V600E inhibitors RAF265 and vemurafenib (17, 20) , in this study we show that PLX3603 did not induce decreased 18 F-FLT uptake in the A375 melanoma xenografts, as measured by ex vivo biodistribution analysis and 18 F-FLT-PET. It is not uncommon that 18 F-FLT uptake does not reflect changes in tumor proliferation. Proliferating tumor cells are not only dependent on uptake of thymidine via the nucleotide transporter (salvage pathway), but thymidine can also be synthesized de novo from deoxyuridine monophosphate via thymidine synthetase. Furthermore, in mice thymidine plasma levels tend to be high and endogenous thymidine may compete with 18 F-FLT (21) , which may explain the low 18 F-FLT uptake at baseline and the lack of reduced 18 F-FLT uptake in the A375 xenografts upon BRAF V600E inhibitor treatment. These results do not exclude 18 F-FLT-PET to monitor the effects of PLX3603 per se, as baseline 18 F-FLT in the present melanoma model was relatively low, possibly precluding measurement of further reduction of FLT uptake.
This study shows that treatment with the specific BRAF V600E inhibitor PLX3603 results in inhibition of the MAPK-pathway in A375 melanoma xenografts, as demonstrated by a decreased pERK expression. The reduced MAPK-pathway activity probably results in a reduced glucose metabolism in A375 tumors, which is reflected by the decreased uptake of 18 F-FDG as assessed by 18 F-FDG-PET. Furthermore, 18 F-FDG-PET allowed the monitoring of dose responses and time course effects of PLX3603 activity. These data demonstrate the potential of 18 F-FDG-PET as a pharmacodynamic marker to noninvasively evaluate the early effects of the BRAF V600E inhibition by PLX3603 and to further define optimal dosing and timing of PLX3603.
